TARA
Protara Therapeutics, Inc.Healthcare·Biotechnology
$4.65
$179M market cap
Revenue
$0.0M
Free Cash Flow
$-38.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was former
2-Year Price History
$4.92+75.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -19.5 | -19.6 | -17.8 | -21.3 | -21.3 | -0.0 | 135.8 | 3.1 | 42.8 | -154.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -19.0 | -19.1 | -17.3 | -17.0 | -17.0 | -0.0 | 155.6 | 3.4 | 46.0 | -113.6% | -- | -- |
Valuation & Metrics
Market Stats
Price$4.65
Market Cap$179M
Enterprise Value$47M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-21.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-35.1M
Free Cash Flow$-38.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-134.2%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares6.0M
Days to Cover9.6
Change (vs Prior)+4.4%
Need at least 2 settlement dates for chart
Employees
Headcount28
Revenue / Employee$0
Gross Profit / Employee$-3,214
Cash Runway
42.5months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
98.2%(+40.6% YoY)
100 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
25.5%(+19.3% YoY)
9 filers
Vanguard, iShares, SPDR
Market makers
0.4%(-0.5% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | $27.2M | $4.83 | +$341K | +$7.4M | +1.2% | $209.29B |
| BlackRock, Inc.Passive | $17.7M | $3.96 | +$5.1M | +$14.4M | -0.2% | $5.69T |
| Velan Capital Investment Management LP | $14.8M | $4.23 | +$0 | +$6.1M | -5.4% | $160M |
| MILLENNIUM MANAGEMENT LLC | $14.8M | $5.11 | +$10.8M | +$11.8M | -0.5% | $127.40B |
| Blackstone Group L.P. | $11.8M | $5.08 | +$1.9M | +$2.7M | +2.9% | $24.20B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $11.0M | $5.21 | +$11.0M | +$11.0M | — | $4.04T |
| Sio Capital Management, LLC | $10.3M | $5.24 | +$1.3M | +$2.4M | -1.2% | $694M |
| ACORN CAPITAL ADVISORS, LLC | $9.1M | $4.67 | +$0 | +$2.5M | +5.8% | $352M |
| Integral Health Asset Management, LLC | $9.1M | $5.30 | −$2.6M | +$1.8M | -0.5% | $1.64B |
| AIGH Capital Management LLC | $8.5M | $5.21 | +$8.5M | +$8.5M | +0.7% | $488M |
| UBS Group AG | $7.3M | $4.31 | +$974K | +$4.0M | -0.3% | $562.11B |
| 5AM Venture Management, LLC | $7.1M | $5.30 | +$0 | +$3.0M | +0.9% | $360M |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $6.1M | $4.01 | +$1.9M | +$4.3M | +2.3% | $1.61T |
| Point72 Asset Management, L.P. | $6.0M | $5.21 | +$5.9M | +$6.0M | +0.9% | $54.88B |
| CITADEL ADVISORS LLC | $5.6M | $3.92 | +$870K | +$3.4M | -0.4% | $138.22B |
| Patient Square Capital LP | $5.4M | $5.21 | +$5.4M | +$5.4M | +3.2% | $538M |
| STATE STREET CORPPassive | $5.2M | $4.73 | +$2.3M | +$4.8M | -0.2% | $2.89T |
| BAKER BROS. ADVISORS LP | $5.1M | $3.91 | +$0 | +$2.3M | -0.5% | $16.13B |
| ADAR1 Capital Management, LLC | $4.9M | $5.32 | −$1.0M | +$4.3M | +8.3% | $1.64B |
| BANK OF AMERICA CORP /DE/ | $4.8M | $5.17 | +$2.2M | +$3.3M | -0.1% | $1.36T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
+0.37%
avg per quarter
Holders (ex-self)
+0.38%
excl. this stock
Buyers (this Q)
+0.07%
73 buyers · $0.08B in
Sellers (this Q)
+0.80%
25 sellers · $0.03B out
alpha coverage: 94% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.3%
how holders react when this stock falls
On quiet Qs
+23.0%
−10% to +10% baseline
On rallies (+10%+)
+34.7%
how they react when this stock rises
Holders' portfolio flow this Q
+0.5%
inflows — adds are organic
Sellers' portfolio flow this Q
-6.4%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.5%
Holder mid (any stock)
-3.7%
Holder rally (any stock)
-10.1%
Biggest decreases this quarter
DRIEHAUS CAPITAL MANAGEMENT LLCexited−$6.7MADAGE CAPITAL PARTNERS GP, L.L.C.exited−$5.6MCatalio Capital Management, LP−$4.5Mα+3.3Maven Securities LTDexited−$4.0MSPHERA FUNDS MANAGEMENT LTD.exited−$3.5MIntegral Health Asset Management, LLC−$2.6Mα-0.5ADAR1 Capital Management, LLC−$1.0Mα+8.3JANE STREET GROUP, LLCexited−$832KAMERIPRISE FINANCIAL INCexited−$821KMonashee Investment Management LLCexited−$666K
New buyers this quarter
Top-5 holders · 36.3%
JANUS HENDERSON GROUP PLC--
BlackRock, Inc.--
Velan Capital Investment Management LP--
MILLENNIUM MANAGEMENT LLC--
Blackstone Group L.P.--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
JANUS HENDERSON GROUP PLC5.2MOpaleye Management Inc.—RA CAPITAL MANAGEMENT, L.P.—Velan Capital Investment Management LP2.8MMILLENNIUM MANAGEMENT LLC2.8MIntegral Health Asset Management, LLC1.8MADAGE CAPITAL PARTNERS GP, L.L.C.—Blackstone Group L.P.2.3MTORONTO DOMINION BANK12KSio Capital Management, LLC2.0M
Analyst Coverage
Analyst Coverage
Analyst Ratings
6
Buy: 6Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Sells ($, 12mo)
$125K
2 txns · 1 insider · 23,732 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-04-08 | SELL | Zummo Jacqueline | officer: Chief R&D Officer | 1,134 | $5.40 | $6K | $512K |
| 2026-04-01 | SELL | Zummo Jacqueline | officer: Chief R&D Officer | 22,598 | $5.26 | $119K | $505K |
Order Flow (FINRA, ~3w lag)
14.8%retail-7.5pp
20.8%dark+2.0pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Protara Therapeutics: A Dilution-Heavy Bio-Engine in Perpetual Financing Mode
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
3/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
6/10
Contextually Acceptable
8/10